The LncRNA MIAT is identified as a regulator of stemness-associated transcript in glioma
- PMID: 36352177
- DOI: 10.1007/s11033-022-07962-5
The LncRNA MIAT is identified as a regulator of stemness-associated transcript in glioma
Abstract
Background: Myocardial infarction-associated transcript (MIAT) is a long non-coding RNA (lncRNA) with altered expression in different diseases and malignancies. In this study, the potential expression and function of lncRNA MIAT in intuition and progression of brain cancer was investigated.
Methods and results: At first, TCGA data analysis demonstrated that lncRNA MIAT is significantly upregulated in various malignancies, especially its expression is dramatically elevated in brain tumors. In line with the data, we further evaluated the expression of MIAT in a series of brain tumor tissue, and our results revealed that the expression of MIAT was noticeably overexpressed in glioblastoma (p = < 0.0001). We further found that the expression of MIAT was markedly upregulated in low-grade brain tumors rather than high-grade ones. To further investigate the biological function of MIAT in brain cancer cells, its expression was suppressed by si-RNA-mediated knocking down. Inhibition of MIAT resulted in reduced proliferation of brain tumor cells followed by cell cycle arrest at the G1 phase, and significant induction of apoptosis, and senescence, but limited the migration ability and epithelial-mesenchymal-transition (EMT). Moreover, knocking-down of MIAT reduced the expression of stemness factors, followed by upregulation of their downstream miRNAs (micro RNAs), let-7a-5p, and miR-29b-3p.
Conclusions: Altogether, our data demonstrated that lncRNA MIAT could control proliferation, migration, and metastasis of brain cancer cells via regulating the Nanog/ Sox2 / let-7a-5p / miR-29b-3p axis. This data could introduce lncRNA MIAT as a novel oncogene in brain cancer pathogenesis.
Keywords: Brain tumors; Cancer Stem Cell; EMT; LncRNA MIAT; Oncogene.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
References
-
- Zhou H-M, Zhang J-G, Zhang X, Li Q (2021) Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct Target Ther 6(1):62. https://doi.org/10.1038/s41392-020-00430-1 - DOI
-
- Werbowetski-Ogilvie TE (2022) From sorting to sequencing in the molecular era: the evolution of the cancer stem cell model in medulloblastoma. FEBS J 289(7):1765–1778. https://doi.org/10.1111/febs.15817 - DOI
-
- Najafi M, Farhood B, Mortezaee K (2019) Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol 234(6):8381–8395. https://doi.org/10.1002/jcp.27740 - DOI
-
- Sun C, Huang L, Li Z, Leng K, Xu Y, Jiang X, Cui Y (2018) Long non-coding RNA MIAT in development and disease: a new player in an old game. J Biomed Sci 25(1):23. https://doi.org/10.1186/s12929-018-0427-3 - DOI
-
- Tang Y, Lei W, Chen Y, Wang X, Hamrick MW, Zhou M (2018) Noncoding RNAs and Stem Cell Function and Therapy. Stem Cells Int 2018:7306034–7306034. https://doi.org/10.1155/2018/7306034 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
